2024-11-05T17:38:05-06:00 2023-12-31 910189318 MOSS ADAMS LLP 4747 EXECUTIVE DR SUITE 1300 SAN DIEGO CA 92121 990 2023-01-01 521842938 J CRAIG VENTER INSTITUTE JCRA 8582001800 4120 CAPRICORN LANE LA JOLLA CA 92037 JOHN CRAIG VENTER CHAIRMAN AND CEO 8582001800 2024-11-05 1 0 PATRICIA J MAYER P00188643 8586271400 2023 2024-10-15 13:58:12Z JOHN CRAIG VENTER 4120 CAPRICORN LANE LA JOLLA CA 92037 20423227 0 X WWW.JCVI.ORG X 1993 MD JCVI IS ADVANCING THE SCIENCE OF GENOMICS THROUGH BOLD INNOVATIONS. OUR MISSION IS TO UNDERSTAND MORE ABOUT THE BIOLOGICAL WORLD, AND TO DEVELOP UNIQUE INSIGHTS AND ANSWERS ABOUT DISEASE, HEALTH, AND THE ENVIRONMENT FOR THE BENEFIT OF ALL. 9 7 134 7 9582 5836 16500408 15104824 0 0 -15395627 18333 27731 9582 1132512 15132739 2934839 2483399 0 0 14376767 13562992 0 0 428398 6002601 5799283 23314207 21845674 -22181695 -6712935 56307767 48982028 9402615 10026647 46905152 38955381 X J. CRAIG VENTER INSTITUTE (JCVI) IS AN INDEPENDENT 501(C)(3) NONPROFIT ORGANIZATION ADVANCING THE SCIENCE OF GENOMICS COMMITTED TO ACCELERATING FOUNDATIONAL SCIENTIFIC RESEARCH TO DRIVE ADVANCES IN HUMAN HEALTH AND ENVIRONMENTAL SUSTAINABILITY. THIS PAST YEAR JCVI COMMITTED RESEARCH EFFORTS IN HUMAN HEALTH, ENVIRONMENTAL SUSTAINABILITY, SYNTHETIC BIOLOGY, AND SOFTWARE TOOLS AND TECHNOLOGY. 0 0 8738224 2412163 0 DEPARTMENT OF HEALTH AND HUMAN SERVICES: TWO MILLION PEOPLE IN THE U.S. ARE DIAGNOSED ANNUALLY WITH LIFE-THREATENING INFECTIONS CAUSED BY ANTIBIOTIC RESISTANT BACTERIA THAT ARE RESPONSIBLE FOR 35,000 DEATHS EACH YEAR WITH AN ECONOMIC IMPACT ESTIMATED TO BE AS MUCH AS $20 BILLION A YEAR IN DIRECT HEALTHCARE COSTS. DUE TO THE SPREAD OF ANTIBIOTIC RESISTANCE, VERY FEW DRUGS REMAIN THAT CAN TREAT THESE INFECTIONS. LED BY DERRICK FOUTS, PHD, (JCVI) AND FUNDED BY THE CENTERS FOR DISEASE CONTROL AND PREVENTION (CDC), THE J. CRAIG VENTER INSTITUTE AND CLEVELAND VA PREVENTION AND INTERVENTION EPICENTER ARE DEVELOPING NOVEL INTERVENTIONS THAT WILL PREVENT THE COLONIZATION AND SPREAD OF ANTIBIOTIC RESISTANT (AR) BACTERIA THAT CAUSE HOSPITAL ACQUIRED INFECTIONS (HAI), AND TO DEVELOP DIAGNOSTICS AND INTERVENTIONS TO COMBAT THE COLONIZATION BY THE RAPIDLY EMERGING FUNGAL PATHOGEN CANDIDA AURIS. RICHARD SCHEUERMANN, PHD, IS LEADING A TEAM OF INVESTIGATORS AT JCVI IN RESPONSE TO THE COVID-19 OUTBREAK. THROUGH HIS NIH-SPONSORED BIOINFORMATICS RESOURCE CENTER PROJECT, HIS TEAM RELEASED A DEDICATED PUBLIC WEB PORTAL FOR THE SARS-COV-2 VIRUS DURING THE EARLY STAGES OF THE OUTBREAK TO ENSURE DATA AND TOOLS ARE ACCESSIBLE TO FRONTLINE RESEARCHERS WORLDWIDE. ADDITIONALLY, IN COLLABORATION WITH INVESTIGATORS FROM LA JOLLA INSTITUTE FOR IMMUNOLOGY, DR. SCHEUERMANN AND HIS TEAM PROVIDED MACHINE LEARNING METHODS TO HELP COMPLETE THE FIRST ANALYSIS THAT IDENTIFIED POTENTIAL TARGETS FOR HUMAN IMMUNE RESPONSES TO SARS-COV-2 INFECTION. THIS INFORMATION IS CRUCIAL TO THE DESIGN AND EVALUATION OF DIAGNOSTICS AND VACCINE CANDIDATES. 799972 0 0 DEPARTMENT OF ENERGY: JCVI IS THE RECIPIENT OF A LARGE COLLABORATIVE ASSISTANCE AWARD FROM THE US DEPARTMENT OF ENERGY. AWARDED TO THE VALUE OF $10.7M. LED BY ANDREW ALLEN, PHD, THE JCVI AND ITS COLLABORATORS, COLORADO STATE UNIVERSITY, VANDERBILT UNIVERSITY AND THE UNIVERSITY OF CALIFORNIA, SAN DIEGO, SEEK TO LEVERAGE SIGNIFICANT RECENT ADVANCES IN DIATOM GENOME ENGINEERING AND METABOLIC MODELING; INCLUDING THE ABILITY TO INTRODUCE CHROMOSOME-LIKE EXPRESSION PLATFORMS, WHICH SUBSTANTIALLY ADVANCE POSSIBILITIES FOR HIGH-THROUGHPUT GENERATION AND SCREENING OF GENETICALLY ENGINEERED DIATOMS. RESEARCH PROPOSED HERE WILL RESULT IN DRAMATIC IMPROVEMENTS IN THE PREDICATIVE CAPACITY OF EXISTING GENOME SCALE METABOLIC MODELS OF DIATOM METABOLISM. FOR THE FIRST TIME ON A LARGE SCALE, FLUXOMICS, WHICH IS COMPOUND SPECIFIC INCORPORATION OF AN ISOTOPICALLY-LABELED FEEDSTOCK, WILL BE USED TO PROVIDE BETTER FIRST STEP CONSTRAINTS ON CO2 ASSIMILATION OF IN DIATOMS. STATE-OF-THE-ART HIGH THROUGHPUT IN VITRO EXAMINATIONS OF NEARLY ALL 200 DIATOM TRANSCRIPTION FACTORS WILL BE CONDUCTED TO BETTER UNDERSTAND REGULATORY ARCHITECTURE UNDERLYING DIATOM METABOLISM AS WELL AS SERVE AS A SOURCE FOR NEW TOOLS FOR GENOME ENGINEERING. TAKEN TOGETHER, RESEARCH PROPOSED HERE WILL ADDRESS CURRENTLY LIMITING BOTTLENECKS THROUGH FOSTERING STATE-OF-THE-ART INTEGRATION OF GENOME-SCALE MODELING WITH GENOME ENGINEERING TO OPTIMIZE ENERGY AND METABOLTE FLUX THROUGH SUBCELLULAR COMPARTMENTS TO PROMOTE EFFICIENT PRODUCTION OF HIGH VALUE AND FUEL-RELATED METABOLITES. 1692603 71236 0 NATIONAL SCIENCE FOUNDATION CONTINUES TO FUND THE J. CRAIG VENTER INSTITUTE (JCVI) IN THE AREAS OF SYNTHETIC BIOLOGY AND INTEGRATIVE ORGANISMAL SYSTEMS CORE PROGRAMS. UNDER THE DIVISION OF MOLECULAR AND CELLULAR BIOSCIENCE AND IN COLLABORATION WITH THE UNIVERSITY OF ILLINOIS MINIMAL BACTERIAL CELL COMPUTATIONAL MODELING TEAM, LED BY XZAN LUTEHY-SCHULTEN, JCVI RESEARCHERS LED BY DR. JOHN GLASS, ARE CARRYING OUT TRANSCRIPTOME AND METABOLOMIC ANALYSES, BIOCHEMICAL AND GENETIC EXPERIEMENTS TO DISCOVER UNKNOWN GENE FUNCTIONS, OPTIMIZATION OF A MINIMAL CELL DEFINED GROWTH MEDIUM, AND CONSTRCUTION OF MINIMAL CELL MUTANTS TO FACILITATE THE WORK OF JCVI AND OTHER GROUPS INVESTIGATING MINIMAL CELL BIOLOGY. THIS IS A MULTI-YEAR STUDY WITH COLLABORATIVE FUNDING OF $2 MILLION.LED BY DR. ANDREW ALLEN AND IN COLLABORATION WITH THE UNIVERSITY OF CALIFORNIA SAN DIEGO (UCSD), JCVI AND UCSD BRING TOGETHER COLLECTIVE EXPERIENCE WITH DIATOM MOLECULAR GENETICS, CURRENT DIATOM MODEL ORGANISMS, MARINE BIOCHEMISTRY AND MICROSCOPY AND OUR RECENT DISCOVERY AND CHARACTERIZATION OF THE HITHERTO UNKNOWN PATHWAY FOR DA BIOSYNTHESIS, TO ESTABLISH PSEUDO-NITZSCHIA SP., AS NEW MODEL DIATOM. IN SO DOING, MOLECULAR BIOLOGICAL METHODS WILL BE DEVELOPED TO ENABLE GENOME-TO-PHENOME INVESTIGATIONS OF THE REGULATION AND BIOSYNTHESIS OF DA. SPECIFICALLY, A METHOD TO TRANSFORM PSEUDO-NITZSCHIA SP DRIVEN BY BACTERIAL CONJUGATION WILL BE DEVELOPED AND DISSEMINATED TO MARINE LABS WORLDWIDE. THE HARMFUL ALGAL BLOOMS (HABS) THREATENING ECOSYSTEMS, FISHERIES AND HUMAN HEALTH WORLDWIDE, ARE DRIVEN BY ONE DIATOM GENUS, PSEUDO-NITZSCHIA, ALONG WITH SEVERAL DINOFLAGELLATE GENERA AND CYANOBACTERIA. IN THE LAST DECADE, VARIOUS SPECIES OF PSEUDO-NITZSCHIA HAVE PRODUCED DEVASTING BLOOMS OF THE NEUROTOXIN, DOMOIC ACID (DA), IN THE COASTAL WATERS OF AUSTRALIA, BRAZIL, CALIFORNIA, CHILE, FRANCE, THE GULF OF MAINE, INDONESIA, ITALY, AND TUNISIA. CURRENTLY, THERE IS GREAT UNCERTAINTY REGARDING HOW OCEAN ACIDIFICATION, INCREASED CONCENTRATIONS OF ATMOSPHERIC CO2, PRECIPITATION, AND NUTRIENT STRESS WILL SHAPE THE PRODUCTIVITY AND GLOBAL RANGE OF PSEUDO-NITZSCHIA SPECIES. INDEED, LONG TERM TRENDS HAVE EMERGED THAT LINK TOXIC PSEUDO-NITZSCHIA SPP. BLOOMS TO MORE FREQUENT DA CONTAMINATION OF SHELLFISH FISHERIES IN THE WARMER OCEAN TEMPERATURES THAT PREVAIL DURING WARMER YEARS. THIS IS A MULTI-YEAR STUDY WITH COLLABORATIVE FUNDING OF $1.6 MILLION.LED BY DR. JOHN GLASS, THE JCVI IS INVESTIGATING THE MECHANISM OF GENOME TRANSPLANTATION, DEVELOPING GENOME TRANSPLANTATION FOR AT LEAST TWO SPECIES OF NON-MYCOPLASMA BACTERIA, AND USING MICROFLUIDICS TECHNOLOGY TO AUTOMATE AND IMPROVE THE EFFICIENCY OF GENOME TRANSPLANTATION. GENOME TRANSPLANTATION, THE INSERTION OF A COMPLETE BACTERIAL GENOME INTO A SUITABLE RECIPIENT CELL SO THAT THE DONATED GENOME COMMANDEERS THE RECIPIENT CELL TO PRODUCE A NEW CELL WITH THE GENOTYPE AND PHENOTYPE OF THE DONATED GENOME, WAS THE FUNDAMENTAL TECHNICAL DEVELOPMENT THAT ENABLED THE CONSTRUCTION OF THE FIRST BACTERIUM WITH A SYNTHETIC GENOME. AT THE ANNOUNCEMENT OF THE CREATION OF THE WORLD'S FIRST SYNTHETIC CELL, JCVI-SYN1.0, THE WORK WAS HERALDED AS A MAJOR ACCOMPLISHMENT FOR MANKIND. TO DATE, GENOME TRANSPLANTATION HAS ONLY BEEN ACHIEVED USING A SMALL SUBSET OF THE ATYPICAL BACTERIA CALLED MYCOPLASMAS. THIS IS A MULTI-YEAR STUDY WITH COLLABORATIVE FUNDING OF $1 MILLION. 38090 0 0 OTHER: AS PART OF THEIR INAUGURAL GRANT CYCLE, THE CONRAD PREBYS FOUNDATION FUNDED THE INSTITUTES RESEARCH WORK IN BOTH CORONARY ARTERY DISEASE AND SARS-COV-2. HEART DISEASE IS THE LEADING CAUSE OF DEATH IN THE US AND CORONARY ARTERY DISEASE (CAD) IS THE MOST COMMON TYPE OF HEART DISEASE, KILLING ~366,000 PEOPLE ANNUALLY IN THE US. ABOUT 6.7% (18.2 MILLION) US ADULTS HAVE CAD AND ~20% OF DEATHS FROM CAD OCCUR BEFORE AGE 65. A LIST OF GENETIC FACTORS LINKED TO CAD HAS BEEN FOUND OVER THE LAST FEW DECADES. BUT THEY ONLY EXPLAIN A SMALL PORTION OF THE HERITABILITY IN CAD. TO BETTER UNDERSTAND THE GENETICS AND ETIOLOGY OF CAD AT GENOMIC LEVEL, MORE RARE GENETIC VARIANTS NEED TO BE INVESTIGATED. LED BY WEIZHONG LI, THIS PROJECT, ANALYZED THE WHOLE GENOME DEEP SEQUENCE DATA OF A LARGE COHORT OF ~1000 CAD PATIENTS. USING THE CLOUD-BASED GENOME ANALYSIS PIPELINE, HUNDREDS OF TERABYTES OF SEQUENCE DATA WERE PROCESSED AND MILLIONS OF VARIOUS TYPES OF GENETIC VARIANTS WERE IDENTIFIED. A LIST OF VARIANTS ARE FOUND TO BE ASSOCIATED WITH CAD AND THE EXTENT OF DISEASE IN CAD. BY USING MACHINE LEARNING APPROACHES, WE BUILT VERY ACCURATE PREDICTIVE MODELS FOR THE PREDICTION OF CAD RISKS AND DISEASE SEVERITY. EARLY WARNING SYSTEM FOR SARS-COV-2 IMMUNE ESCAPE PROJECT. NEUTRALIZING ANTIBODIES ELICITED AGAINST THE SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS (SARS-COV-2) SPIKE PROTEIN IS WIDELY ACCEPTED AS THE MAIN CORRELATE OF PROTECTION. TO BETTER UNDERSTAND THE ROLE OF ANTIBODIES IN NEUTRALIZATION AND PROTECTION, JCVI, LED BY RICHARD SCHEUERMANN, PHD, AND GENE TAN, PHD, IS CONSTRUCTING A PANEL OF CHIMERIC PSEUDOVIRUSES (BASED ON THE VESICULAR STOMATITIS VIRUS PLATFORM) THAT WE HYPOTHESIZE CAN REVEAL THE IMMUNOLOGICAL DOMINANT AND SUBDOMINANT ANTIGENIC REGIONS OF THE SPIKE PROTEIN. NOTABLY, OUR APPROACH CAN IDENTIFY SUBDOMINANT REGIONS WITHIN THE SPIKE THAT ARE HIGHLY CONSERVED EVEN AMONGST SARS-COV-2 VARIANTS OF CONCERN (VOCS). COVID19 CONTINUES TO IMPACT GLOBAL HEALTH, HIGHLIGHTING THE NEED TO DEVELOP NOVEL THERAPEUTICS. MARCELO FREIRE, PHD, AND HIS LABORATORY DISCOVERED THAT SALIVA IS A BIOFLUID IMPORTANT FOR MEASURING THE VIRUS BUT ALSO THE IMMUNE RESPONSE PRESENTING DIVERSE IMMUNE CELL POPULATIONS. WHITIN SALIVA, WE FIND VARIOUS ANTIVIRAL, ANTI-INFLAMMATORY AND ANTI-BACTERIAL FUNCTIONS. DIFFERENT FROM BLOOD, SALIVARY IMMUNE CELLS ARE IN DIRECT CONTACT WITH THE LIVE VIRUS. IN THIS PROPOSAL WE INVESTIGATED (I) THE COMPOSITION OF ANTIVIRAL IMMUNE CELLS, (II) THE PROTEIN SEQUENCE OF ANTIVIRAL MOLECULES DERIVED FROM INNATE IMMUNE CELLS, AND (III) THEIR MECHANISM OF ACTION. THE FREIRE LAB HAVE SUCCESSFULLY COLLECTED SAMPLES FROM COVID-19 AND HEALTHY CONTROL SAMPLES AND INITIATED SEQUENCING OF SALIVA CELLS IN HEALTH AND IN COVID-19. IN ADDITION, WE ALSO RECRUITED SAMPLES LONGITUDINALLY AT JCVI TO EVALUATE HEALTHY VERSUS DISEASE. TO DATE, WE COMPLETED IMMUNOGLOBULIN IMMUNOASSAYS OF ALL OUR SAMPLES INCLUDING INVESTIGATIONS TO CUSTOM ELISA ASSAYS FOR SARS-COV-2 ANTIGENS (RBD, S1, S2, NP PROTEINS). WE HAVE IDENTIFIED THAT SALIVARY IMMUNOGLOBULIN IGA AS HIGHLY SIGNIFICANT COMPARED TO BLOOD PLASMA LEVELS. SEVERAL MARKERS FROM IGG AND IGA RESPONSES WERE FOUND IN SALIVA AS WELL AS PLASMA. SIMPLE LINEAR REGRESSION MODEL VERIFIED SIGNIFICANT CORRELATIONS BETWEEN SALIVA AND PLASMA ANTIBODY RESPONSES, SPECIFICALLY FOR THE IGA (P=0.001), IGG (P=0.037), AND IGM (P=0.0054) SPECIFIC TO THE SARS-COV-2 RECEPTOR BINDING SITE (RBD). THESE ARE ANTIVIRAL MOLECULES THAT HAVE POTENTIAL TO BLOCK VIRAL ACTIVITY. TO TEST THIS FURTHER FROM OUR ASSAYS, JCVI PERFORMED A NEUTRALIZATION ASSAY AND COMPARATIVE ANALYSIS TO UNDERSTAND IF THESE MOLECULES HAVE A FUNCTIONAL RESPONSE. DESPITE THAT SALIVA CONTAINED ROBUST IGA RESPONSE TO THE SARS-COV-2, WHICH WAS EVEN HIGHER THAN PLASMA, MOST OF SALIVA SAMPLES DEMONSTRATED LEVEL OF NEUTRALIZATION OF VESICULAR STOMATITIS VIRUS (VSV) PSEUDOVIRUSES BEARING S OF SARS-COV-2 (RVSV-GFPG*SPIKE). IT WAS CONTRASTED WITH THAT THE PLASMA DISPLAYED A SIGNIFICANT LEVEL OF NEUTRALIZING ACTIVITY EVEN FROM HEALTHY INDIVIDUALS. THESE RESULTS SUGGEST THAT THE ORAL MUCOSAL IMMUNE COMPONENTS COOPERATE WITH SYSTEMIC IMMUNE RESPONSE IN RESPONSE TO THE SARS-COV-2 INFECTION. SALIVA AND PLASMA SAMPLES CONTAINED SIGNIFICANTLY HIGHER LEVELS OF SARS-COV-2 SPECIFIC ANTIBODIES THAN HEALTHY AND WE DISCOVERED MULTIPLE PEPTIDES PRESENT A ROLE AGAINST VIRAL PARTICLES. ULTIMATELY, THIS PROJECT AIMS TO MAP THE SALIVARY MOLECULAR CONTENT WHEN EXPOSED TO THE VIRUS. WE AIM PROVIDE TO THE SCIENTIFIC COMMUNITY A NEW LAYER OF IMMUNE RESPONSE COMPOSITION AND FUNCTION RELATED TO MUCOSAL LINING WHEN FACING VIRAL ATTACK. THIS WILL THEN GUIDE NEW CLINICAL APPROACHES WITH THE FORMATION OF THE THERAPEUTICS THAT EMULATE HOW AND WHY THE MUCOSAL TISSUES KEEP DISEASE IN CHECK. SANJAY VASHEE, PHD, COLLABORATING WITH INVESTIGATORS AT THE UNIVERSITY OF MARYLAND TO USE SYNTHETIC GENOMICS TO DEVELOP A SARS-COV-2 INFECTIOUS CLONE. THEY ARE PAIRING THIS WITH A RAPID, MODULAR REVERSE GENETIC SYSTEM TO ASSESS GENOMIC VARIANTS IDENTIFIED IN THE WEALTH OF GLOBAL SEQUENCING DATA, DEVELOP AND TEST VACCINE CANDIDATES, AND GENERATE NEEDED REAGENTS, INCLUDING FLUORESCENT AND TAGGED VIRUS STRAINS. MARCELO FREIRE, PHD, IS LEADING EFFORTS IN THE DEVELOPMENT OF A SALIVARY SEROLOGICAL AND IMMUNE TESTING. MONITORING SALIVA IMMUNITY PROVIDES NON-INVASIVE MOLECULAR INFORMATION, ESSENTIAL FOR DIAGNOSTICS, AND RESPONSE TO THERAPY DURING THE PANDEMIC. HIS LABORATORY IS COMPARING COVID-19 PATIENTS' BLOOD AND SALIVARY IMMUNOGLOBULINS LEVELS TO FIND BETTER WAYS TO EVALUATE IMMUNE RESPONSE TO SARS-COV-2. 38090 0 0 11268889 1 1 0 0 0 0 0 1 0 0 1 0 0 1 1 1 1 0 0 0 1 1 0 0 0 0 0 1 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 14 0 1 134 1 1 1 0 0 0 0 0 0 0 0 0 1 0 X 9 7 1 0 0 0 0 0 0 1 1 0 0 1 1 1 1 1 1 1 1 0 AL AR CA FL GA HI IL KS KY MA MD MI MN MS NC ND NH NJ VA X KATHARINE WARDLE 8582001800 4120 CAPRICORN LANE LA JOLLA CA 92037 VENTER JOHN CRAIG CHAIRMAN & CEO 40.00 X X 1190386 0 18720 KOWALSKI HEATHER CHIEF OPERATING OFFICER 40.00 X X 359154 0 19533 PEAKE ANTONY G VP RESEARCH ADMINISTRATION 40.00 X 301718 0 8314 SCHEUERMANN RICHARD H DIRECTOR, LA JOLLA CAMPUS 40.00 X 282405 0 26860 MULLEN JILL SR. VP OF PHILANTHROPY 32.00 X 281136 0 27622 YUMUL MARY VP OF HUMAN RESOURCES 40.00 X 256429 0 14463 STOUT MARTIN CHIEF TECHNOLOGY OFFICER 40.00 X 220186 0 13652 SINGH INDRESH SR. SOFTWARE ENGINEER 40.00 X 217234 0 12243 STAYEAS TIMOTHY NETWORK TEAM LEAD 40.00 X 214596 0 14204 FOUTS DERRICK PROFESSOR 40.00 X 211599 0 7712 SHADFAN AIDA VP OF FINANCE (THRU 09/23) 40.00 X 202897 0 7858 ADELSON JULIE VP, LEG. AFFRS/GENERAL COUNSEL 20.00 X 196958 0 6600 WARDLE KATHARINE TREAS/VP OF FINANCE (FROM 09/23) 40.00 X 139527 0 7989 BADR-EL-DIN AMIN PHD TRUSTEE 1.00 X 0 0 0 BRENNER DAVID TRUSTEE (FROM 2/8/23) 1.00 X 0 0 0 NORRBY ERLING TRUSTEE 1.00 X 0 0 0 PERRY MEREDITH TRUSTEE (FROM 2/8/23) 1.00 X 0 0 0 RUGGLES RUDY TRUSTEE 1.00 X 0 0 0 WEI WU TRUSTEE 1.00 X 0 0 0 WOLF RICHMOND TRUSTEE 1.00 X 0 0 0 4074225 0 185770 34 0 1 0 MOSS ADAMS LLP 4747 EXECUTIVE DRIVE SUITE 1300 SAN DIEGO CA 92121 ACCOUNTING AND AUDIT SERVICES 145815 TB CONSULTING 8328 E HARTFORD DRIVE SUITE 102 SCOTTSDALE AZ 85255 COMPUTER SERVICE CONSULTANT 145115 2 12889795 2215029 15104824 627098 627098 4681723 5248840 41648 -567117 -41648 -608765 -608765 K-1 PASSTHROUGH 900001 9582 9582 9582 15132739 0 9582 18333 2412163 2412163 71236 71236 3002758 3002758 9486427 6126044 3005073 355310 273405 168167 95483 9755 57877 49956 5024 2897 742525 367437 353777 21311 130759 130759 158050 158050 104695 104695 290985 130693 160292 103996 81844 18454 3698 698310 184783 513527 1196618 300737 890702 5179 172991 96071 60995 15925 415542 138190 277352 392982 392982 LAB EQUIPMENT AND SUPPL 1312681 1054937 257744 ALL OTHER EXPENSES 821674 86631 720720 14323 21845674 11268889 10148387 428398 5102233 2971911 395507 1274704 15575492 13669583 7507 11598 311397 576720 14973953 13367545 1858655 1606408 27086686 23360705 689927 553787 5280363 4956612 56307767 48982028 2689803 2674079 2973249 4052856 3739563 3299712 9402615 10026647 X 34764101 29780872 12141051 9174509 46905152 38955381 56307767 48982028 X -6712935 1742746 -2979582 X 0 1 X 1 1 1 X 21442951 18613419 24288254 16500408 15104824 95949856 14850000 14850000 21442951 18613419 24288254 31350408 15104824 110799856 110799856 1158537 905885 855862 726080 627098 4273462 15119 6041 21160 115094478 669522 0.96270 0.93420 X RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED 2545000 X X X 0 1395244 675640 719604 13578709 12691905 886804 1606408 OTHER ASSETS 2725900 RIGHT OF USE ASSETS 2230712 4956612 LEASE LIABILITY 3299712 3299712 X 16761208 1742746 1742746 15018462 104695 9582 114277 15132739 24710979 2970000 2970000 21740979 104695 104695 21845674 PART III, LINE 4: COLLECTION OF SCIENTIFIC WRITINGS RELEVANT TO GENOMIC RESEARCH. PART X, LINE 2: THE INSTITUTE IS A NOT-FOR-PROFIT ORGANIZATION EXEMPT FROM FEDERAL INCOME TAXES UNDER SECTION 501(C)(3) OF THE INTERNAL REVENUE CODE. THE INSTITUTE DOES NOT BELIEVE THERE ARE ANY MATERIAL UNCERTAIN TAX POSITIONS AND ACCORDINGLY, NO PROVISION FOR INCOME TAXES HAS BEEN MADE IN THE ACCOMPANYING FINANCIAL STATEMENTS. THE INSTITUTE IS SUBJECT TO ROUTINE AUDITS BY TAXING JURISDICTIONS; HOWEVER, THERE ARE CURRENTLY NO AUDITS FOR ANY TAX PERIOD IN PROGRESS. PART XI, LINE 4B - OTHER ADJUSTMENTS: K-1 PASSTHROUGH 9,582. 1 CAYMAN ISLANDS 0 0 INVESTMENTS 145119 CENTRAL AMERICA AND THE CARIBBEAN - ANTIGUA & BARBUDA, ARUBA, BAHAMAS, 0 0 PROGRAM SERVICES RESEARCH SUBGRANTS 40152 SOUTH AMERICA 0 0 PROGRAM SERVICES RESEARCH SUBGRANTS 31084 0 0 0 0 0 0 216355 0 216355 CENTRAL AMERICA AND THE CARIBBEAN UNIVERSITY OF WEST INDIES, PROGRAM SERVICES/RESEARCH SUBGRANTS 40152 WIRE OR CHECK 0 SOUTH AMERICA RESEARCH SUBGRANTS 31084 WIRE OR CHECK 0 2 0 0 0 0 0 1 0 PART I, LINE 2: EACH SUBGRANT IS A PASS THROUGH GRANT FROM A FEDERAL OR NON-FEDERAL GRANT OR CONTRACT AWARDED TO J. CRAIG VENTER INSTITUTE. ALL EXPENSES ARE MONITORED AS INVOICED AT LEAST QUARTERLY, BUT IN MOST CASES MONTHLY. THE INVOICES ARE REVIEWED AND APPROVED BASED ON RECEIPT OF GOODS OR SERVICES AND AGAINST AN APPROVED BUDGET. PART I, LINE 3: ACCRUAL BASIS PART II, LINE 1: ACCRUAL BASIS 1 CASE WESTERN RESERVE UNIVERSITY 10900 EUCLID AVENUE NORD HALL CLEVELAND OH 441067037 341018992 501(C)(3) 409716 0 RESEARCH SUBGRANT COLORADO STATE UNIVERSITY 6015 CAMPUS DELIVERY FORT COLLINS CO 80523 846000545 GOVT 147113 0 RESEARCH SUBGRANT DUKE UNIVERSITY PO BOX 602651 CHARLOTTE NC 282602651 560532129 501(C)(3) 201837 0 RESEARCH SUBGRANT GLOBAL ALGAE INNOVATIONS 486 LIVE OAK DRIVE EL CAJON CA 92020 455319556 22057 0 RESEARCH SUBGRANT LELAND STANFORD JR UNIVERSITY 3145 PORTER DRIVE PALO ALTO CA 94304 941156365 501(C)(3) 79880 0 RESEARCH SUBGRANT NORTHWESTERN UNIVERSITY 633 CLARK STREET G547 EVANSTON IL 60208 362167817 501(C)(3) 87777 0 RESEARCH SUBGRANT RHODE ISLAND HOSPITAL 1 HOPPIN STREET BOX 42 SUITE 1300 PROVIDENCE RI 029034923 050258954 501(C)(3) 256018 0 RESEARCH SUBGRANT SANTA FE INSTITUTE 1399 HYDE PARK ROAD SANTA FE NM 875018943 850325494 501(C)(3) 30395 0 RESEARCH SUBGRANT UNIVERSITY OF ALABAMA BIRMINGHAM 1720 2ND AVENUE SOUTH BIRMINGHAM AL 35294 636005396 GOVT 46654 0 RESEARCH SUBGRANT UNIVERSITY OF CALIFORNIA SAN DIEGO 9500 GILMAN DRIVE LA JOLLA CA 92037 566001393 GOVT 628139 0 RESEARCH SUBGRANT UNIVERSITY OF MARYLAND 4300 TERRAPIN TRAIL COLLEGE PARK MD 20742 526002033 GOVT 200549 0 RESEARCH SUBGRANT VANDERBILT UNIVERSITY 2201 WEST END AVENUE NASHVILLE TN 37235 620476822 501(C)(3) 302028 0 RESEARCH SUBGRANT 11 1 PART I, LINE 2: EACH SUBGRANT IS A PASS THROUGH GRANT FROM A FEDERAL OR NON-FEDERAL GRANT OR CONTRACT AWARDED TO J. CRAIG VENTER INSTITUTE. ALL EXPENSES ARE MONITORED AS INVOICED AT LEAST QUARTERLY, BUT IN MOST CASES MONTHLY. THE INVOICES ARE REVIEWED AND APPROVED BASED ON RECEIPT OF GOODS OR SERVICES AND AGAINST AN APPROVED BUDGET. X 1 1 X X X X 0 0 0 0 0 0 0 0 0 VENTER JOHN CRAIG CHAIRMAN & CEO 1160389 0 0 0 29997 0 13200 0 5520 0 1209106 0 0 0 KOWALSKI HEATHER CHIEF OPERATING OFFICER 341154 0 0 0 18000 0 13200 0 6333 0 378687 0 0 0 PEAKE ANTONY G VP RESEARCH ADMINISTRATION 278322 0 0 0 23396 0 8314 0 0 0 310032 0 0 0 SCHEUERMANN RICHARD H DIRECTOR, LA JOLLA CAMPUS 261409 0 0 0 20996 0 10624 0 16236 0 309265 0 0 0 MULLEN JILL SR. VP OF PHILANTHROPY 263468 0 0 0 17668 0 10266 0 17356 0 308758 0 0 0 YUMUL MARY VP OF HUMAN RESOURCES 235629 0 0 0 20800 0 9533 0 4930 0 270892 0 0 0 STOUT MARTIN CHIEF TECHNOLOGY OFFICER 213427 0 0 0 6759 0 6206 0 7446 0 233838 0 0 0 SINGH INDRESH SR. SOFTWARE ENGINEER 191806 0 0 0 25428 0 7775 0 4468 0 229477 0 0 0 STAYEAS TIMOTHY NETWORK TEAM LEAD 194354 0 0 0 20242 0 8247 0 5957 0 228800 0 0 0 FOUTS DERRICK PROFESSOR 181599 0 0 0 30000 0 7712 0 0 0 219311 0 0 0 SHADFAN AIDA VP OF FINANCE (THRU 09/23) 188690 0 0 0 14207 0 7858 0 0 0 210755 0 0 0 ADELSON JULIE VP, LEG. AFFRS/GENERAL COUNSEL 168158 0 0 0 28800 0 6600 0 0 0 203558 0 0 0 PART I, LINE 1A SCHEDULE J, PART I, LINE 1A: TAX INDEMIFICATION AND GROSS-UP PAYMENTS - CERTAIN AWARDS ARE GROSSED UP FOR INCOME TAX AND INCLUDED AS TAXABLE COMPENSATION. FORM 990, PART VI, SECTION A, LINE 2 BOARD MEMBERS HEATHER KOWALSKI AND J. CRAIG VENTER HAVE A FAMILY RELATIONSHIP. FORM 990, PART VI, SECTION B, LINE 11B THE FORM 990 IS REVIEWED BY MANAGEMENT AND THE AUDIT COMMITTEE. A COMPLETE COPY OF THE FORM 990 AND SUPPORTING SCHEDULES WAS PROVIDED TO THE FULL BOARD FOR REVIEW PRIOR TO BEING FILED. FORM 990, PART VI, SECTION B, LINE 12C JCVI MONITORS COMPLIANCE TO ITS CONFLICT OF INTEREST POLICY THROUGH AN ANNUAL SOLICITATION OF CONFLICT OF INTEREST STATEMENTS FROM TRUSTEES, OFFICERS, AND EMPLOYEES. IF A PERSON HAS A CONFLICT WITH RESPECT TO A TRANSACTION, SUCH PERSON IS NOT ALLOWED TO VOTE ON THAT TRANSACTION. FORM 990, PART VI, SECTION B, LINE 15 JCVI USES AN OUTSIDE COMPENSATION CONSULTANT TO PROVIDE A LIST OF COMPARABLE SALARIES FOR THE CEO AND OFFICERS THESE ARE REVIEWED BY THE JCVI COMPENSATION COMMITTEE AND CEO BEFORE A FINAL DETERMINATION IS MADE. THIS PROCESS WAS DOCUMENTED AND LAST DONE IN OCTOBER 2018. FORM 990, PART VI, SECTION C, LINE 19 THE ORGANIZATION'S FINANCIAL STATEMENTS, GOVERNING DOCUMENTS, AND CONFLICT OF INTEREST POLICY ARE MADE AVAILABLE TO THE PUBLIC UPON REQUEST. FORM 990, PART XI, LINE 9: K-1 PASSTHROUGH -9,582. DONATED RENT -2,970,000.